Retos actuales de la quimioterapia tras la Refractariedad al Estrategias terapéuticas del nuevo escenario del cáncer de mama avanzado por perfil de paciente

Basal-like 1: Cell cycle,

DNA repair and

proliferation genes

Basal-like 2: Growth factor

signaling (EGFR, MET, Wnt,

IGF1R)

IM: Immune cell

processes (medullary

breast cancer)

M: Cell motility and

differentiation, EMT

processes

MSL: Similar to M but

growth factor signaling, low

levels of proliferation genes

(metaplastic cancers)

LAR: Androgen receptor

and downstream genes,

luminal features

PARPi,

DNA damaging agents

homologous recombination

deficiency assay (BRCA-1 ness)

EGFR (cetuximab, lapatinib)

Self-renewal pathways (stem cell)

Wnt

Notch (PF03084014, AACR 2012

Immune check point

PD1/PDL1, CTLA4

Vaccines: MUC1, NYO-ESO1

Agents targeting androgen receptor

(enzalutamide, bicalutamide, etc)

(eribulin?) Plus

PI3Ki, RAS/MEK/Erk,

MET, PTEN

etc, etc

TNBC Subtypes: Research Strategies